Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Brown, 2016, Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Metabolism, 65, 1080, 10.1016/j.metabol.2015.11.008 NIH NIoDaDaKDw. Nonalcoholic fatty liver disease and NASH. 2018. Patel, 2017, Baseline parameters in clinical trials for nonalcoholic steatohepatitis: recommendations from the liver forum, Gastroenterology, 153, 10.1053/j.gastro.2017.07.024 Hagstrom, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027 Marchesini, 2001, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844 Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 Adams, 2017, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut, 66, 1138, 10.1136/gutjnl-2017-313884 Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257 Kozlitina, 2014, Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 46, 352, 10.1038/ng.2901 Abul-Husn, 2018, A protein-truncating HSD17B13 variant and protection from chronic liver disease, N Engl J Med, 378, 1096, 10.1056/NEJMoa1712191 Mancina, 2016, The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent, Gastroenterology, 150, 10.1053/j.gastro.2016.01.032 Boyle, 2018, The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease, J Hepatol, 68, 251, 10.1016/j.jhep.2017.11.006 Zelber-Sagi, 2018, High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance, J Hepatol, 68, 1239, 10.1016/j.jhep.2018.01.015 Ratziu, 2018, Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the Phase 2 CENTAUR study, J Hepatol, 68, S1, 10.1016/S0168-8278(18)30221-6 Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774 Corey, 2019, Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial, Aliment Pharmacol Ther, 10.1111/apt.15216 Becker, 1996, Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study, Hepatology, 23, 1025, 10.1002/hep.510230513 Ajmera, 2017, Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease, Hepatology, 65, 65, 10.1002/hep.28776 Allen, 2013, Assessing the drinking status of liver transplant patients with alcoholic liver disease, Liver Transpl, 19, 369, 10.1002/lt.23596 Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 10.1053/j.gastro.2016.01.038 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929 Friedman, 2018, A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis, Hepatology, 67, 1754, 10.1002/hep.29477 Thanda Han, 2018, Rates and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis, Clin Gastroenterol Hepatol Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 10.1053/j.gastro.2015.04.005 Zelber-Sagi, 2007, Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study, J Hepatol, 47, 711, 10.1016/j.jhep.2007.06.020 Liang, 2014, Rapid and reagentless detection of microbial contamination within meat utilizing a smartphone-based biosensor, Sci Rep, 4, 5953, 10.1038/srep05953 Health FftNIo. Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE). 2018. website EIMIJU. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS). US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment, Guidance for Industry (Draft Guidance). Ratziu, 2018, A critical review of endpoints for non-cirrhotic NASH therapeutic trials, J Hepatol, 68, 353, 10.1016/j.jhep.2017.12.001 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 10.1053/j.gastro.2015.04.043 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease, Gastroenterology, 10.1053/j.gastro.2018.04.034 Ripoll, 2016, Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?), Hepatology, 63, 660, 10.1002/hep.28273 Ripoll, 2007, Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, 481, 10.1053/j.gastro.2007.05.024 Ripoll, 2015, Serum albumin can identify patients with compensated cirrhosis with a good prognosis, J Clin Gastroenterol, 49, 613, 10.1097/MCG.0000000000000207 Harrison, 2018, Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis, Gastroenterology, 10.1053/j.gastro.2018.07.006 Goyal, 2016, The progression and natural history of pediatric nonalcoholic fatty liver disease, Clin Liver Dis, 20, 325, 10.1016/j.cld.2015.10.003 Anderson, 2015, The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis, PLoS ONE, 10, 10.1371/journal.pone.0140908